Trial intelligence / Profile preview

MAGNITUDE-A phase 3 trial of peginterferon lambda-1a + daclatasvir + ribavirin in chronic hepatitis C patients with mild or moderate hemophilia

NL-OMON39678Phase 3Active, not recruiting

Sponsor

Bristol Myers Squibb

Start

Mar 2013

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1